Yong Jae Lee, MD, PhD, discusses the clinical relevance of the preliminary safety of nivolumab for resectable mismatch repair–deficient endometrial cancer.
Yong Jae Lee, MD, PhD
Advertisement
Yong Jae Lee, MD, PhD, is from the Yonsei University College of Medicine
Articles by Yong Jae Lee, MD, PhD
Yong Jae Lee, MD, PhD, discusses key efficacy outcomes with nivolumab monotherapy in completely surgically resectable dMMR endometrial cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5